Selling Your Veterinary Practice to AmeriVet: A Vet’s 2026 Guide

Key takeaways

• AmeriVet Veterinary Partners is among the most active US mid-market veterinary practice acquirers in 2025-2026 per AmeriVet company materials, headquartered in San Antonio, Texas.
• AmeriVet is owned by AEA Investors and Oaktree Capital per public ownership disclosures — a dual-sponsor PE structure common to larger veterinary platforms.
• The partnership model is a distinguishing feature of AmeriVet’s acquisition approach per AmeriVet company materials. Sellers commonly retain 20 to 40 percent equity in the practice under a partnership structure with negotiated put/call buyout mechanics.
• AmeriVet’s general approach is to preserve local practice branding post-acquisition per AmeriVet company materials. The integration focus is operational support, not brand consolidation.
• The partnership-term negotiation is where the AmeriVet buyer choice matters most. The headline cash-at-close number matters, but the retained-equity buyout formula, liquidity timeline, and governance rights often represent 20 to 40 percent of total deal value and shape the seller’s outcome over the multi-year partnership period.
• The most reliable way to know what AmeriVet — or any major buyer — would actually pay for your specific practice is to run a structured competitive process. We call ours the Elite Selling System: we hand-select and vet every buyer who gets to bid, the way a doorman with a velvet rope lets in only the right people, then run a private bidding window inside that vetted group. AmeriVet is invited inside that rope on practices that fit their criteria — and when they bid against a curated group of qualified competitors, the number is reliably very different from what they would offer in a direct, single-bidder conversation.

AmeriVet conversations show up in our practice on a particular cadence. A vet — sometimes growth-mode, sometimes years past growth-mode — has received a partnership term sheet from a major buyer’s deal team.

The cash-at-close on the majority stake reads fair against industry comps. The retained-equity percentage sits inside the typical band of 20 to 40 percent.

The put/call mechanics are defined to a future buyout window, with a formula price tied to a multiple of practice-level EBITDA. The doctor-friendly framing is real, and the document reads like it was drafted by lawyers who’d negotiated a hundred of these before — because they had.

The question the owner brings to the conversation is almost never about the headline number on the cash-at-close line. It’s a version of the same question we hear repeatedly: is this partnership formula a good one, and what would the field offer if they knew this term sheet existed?

That’s the right question for AmeriVet specifically, because for AmeriVet the negotiation isn’t really about the cash multiple. It’s about the structural mechanics of the retained equity — the buyout multiple, the EBITDA-protection clauses, the governance carve-outs, the platform-exit alignment.

Those terms determine whether the partnership produces materially higher total economic value than a straight 100 percent sale, or whether it produces a slow leak across the hold period.

What follows is the same picture I’d lay out over dinner if a vet handed me an AmeriVet term sheet and asked what to do with it. Who AmeriVet is, how the partnership model actually works in practice, where the leverage sits in the structural negotiation, and how to think about AmeriVet against the other partnership-model and 100-percent buyers who’d compete for the same practice.

Quick facts on AmeriVet Veterinary Partners

AmeriVet Veterinary Partners is a private equity-backed veterinary practice partner headquartered in San Antonio, Texas. AmeriVet operates a US footprint of multi-doctor general practice and specialty hospitals per AmeriVet company materials, with growth driven primarily by acquisitions of established practices in markets where AmeriVet builds regional density.

AmeriVet was founded in the late 2010s as one of the next-generation veterinary consolidators positioned around the partnership model — emphasizing co-ownership with selling veterinarians rather than 100 percent acquisition as the standard transaction structure. That positioning has been a consistent part of the AmeriVet brand and external messaging per AmeriVet company materials.

The dual-sponsor ownership matters. AmeriVet is owned by AEA Investors and Oaktree Capital per public ownership disclosures.

AEA Investors is a New York-based private equity firm with a significant healthcare services practice. Oaktree Capital is a Los Angeles-based investment manager with substantial private equity, credit, and alternative investment activity.

The dual-sponsor structure is common among larger PE-backed platforms and typically reflects the scale of capital required to support a sustained acquisition program.

AmeriVet’s mid-market positioning — focused on multi-doctor general practice and specialty hospitals in the $2 million-plus revenue range, rather than the largest specialty platforms or the smallest single-doctor practices — has made the company one of the most active mid-market bidders in 2025-2026 per the broader Capstone Partners and Octus coverage of the sector.

What AmeriVet actually pays for veterinary practices in 2026

The consistent pattern we see on partnership deals. When a multi-doctor practice receives a direct partnership term sheet from any major partnership-model buyer — AmeriVet included — the terms reflect what the buyer perceives the seller will accept without comparison. The structural dimensions that carry the most long-term economic weight (the put formula multiple, the EBITDA base definition, the governance carve-outs, the integration protections, the interim liquidity rights) tend to be drafted toward the buyer side of the table in any first-draft document, simply because there is no structural pressure in a one-on-one conversation to draft them otherwise.

Inside a properly structured competitive process, where multiple qualified partnership-model bidders are underwriting the same practice in parallel, every one of those structural dimensions tends to move. The dynamic is not unique to AmeriVet.

It is the basic mechanics of how partnership-model term sheets get calibrated to the leverage in the room.

AmeriVet does not publish a standard price sheet for any specific practice profile. Per industry M&A commentary (Octus, Capstone Partners, 2025-2026), competitive outcomes for strong multi-doctor general practices in the $2 million-plus revenue range tend to land in the low-teens EBITDA range across the major buyer pool.

The actual number for any specific practice depends heavily on whether other buyers are at the table and the specific profile of the practice. AmeriVet participates in this competitive band when they bid on qualifying practices, with the specific offer on any specific deal negotiated case by case under confidentiality.

For specialty hospitals, the broader market generally values these higher than comparable GP practices per industry research. AmeriVet has expanded into specialty acquisitions per AmeriVet company materials and may bid as a buyer for qualifying specialty platforms.

For larger multi-location groups ($10 million-plus revenue, $2 million-plus EBITDA), the multiple range typically extends higher than for single-location GP practices, with deal sizes scaling into the eight-figure-plus range. AmeriVet’s acquisition capacity and dual-sponsor capital base mean the platform is an active bidder for larger multi-location groups when the practice profile matches strategic fit.

For practices below the $2 million revenue threshold or single-doctor practices, the buyer pool generally shifts toward regional PE-backed groups, smaller consolidators, and individual buyers. AmeriVet’s published focus has been on multi-doctor mid-market practices rather than single-doctor or very small platforms.

The cash-at-close reality

In a partnership transaction, the “headline number” most owners track is misleading by construction. The actual total economic value of an AmeriVet partnership deal is the sum of three components, all of which are negotiated separately and all of which can move in a competitive process: the cash wired at closing for the majority stake AmeriVet acquires, the present-value of the retained-equity buyout payment that lands in year five (or whenever the put/call window opens), and any earnout component layered on top. 2025-2026 healthcare M&A commentary from Dechert LLP, Holland & Knight, and Capstone Partners shows the broader PE-backed pool concentrating the majority of nominal deal value in the cash-at-close component — but the present-value of the retained-equity component, modeled honestly with realistic discount rates and protective formula provisions, often represents the largest swing factor in the total economic outcome.

The AmeriVet-specific structure typically follows the partnership template: AmeriVet acquires 60 to 80 percent of the practice for cash at the closing table; the seller retains 20 to 40 percent as direct practice-level equity (not platform-level rollover); the retained equity is bound by a contractual put/call mechanism with a formula price tied to practice EBITDA at the future buyout date. The specific allocation across components and the precise mechanics of the buyout formula are negotiated case by case and not publicly enumerated by AmeriVet.

Two sentences worth memorizing before any negotiation: the headline percentage AmeriVet acquires is less important than the formula multiple at the put window, and the formula multiple at the put window is less important than the EBITDA-protection clauses that govern what counts in the EBITDA at the buyout date.

The partnership model, in depth

Because the partnership model is a distinguishing feature of AmeriVet’s acquisition approach per AmeriVet company materials, sellers evaluating an AmeriVet offer benefit from understanding how partnership structures generally work and where the specific negotiation points concentrate.

The basic structure. AmeriVet acquires a majority stake in the practice (commonly 60 to 80 percent in partnership deals across the broader market per MB Law Firm’s 2025 commentary on healthcare M&A trends). The seller retains a minority stake (commonly 20 to 40 percent) as direct equity in the practice itself.

The retained equity is not “rollover” in the traditional sense — it is direct equity in the practice rather than equity in the platform-level holding company. That distinction matters because it ties the retained value to the specific practice’s performance rather than to the broader AmeriVet platform’s performance.

The buyout mechanics. A contractual put/call mechanism defines the buyout date and formula price for the retained equity. The seller typically gets a “put” right to require AmeriVet to buy back the retained equity at a defined future date (commonly year 5 in many partnership structures across the broader market) at a formula-based price tied to the practice’s then-current performance.

AmeriVet typically gets a “call” right to require the seller to sell the retained equity at the same defined date and formula. The mechanics of the formula — what multiple, what EBITDA base, what protective provisions on the EBITDA calculation — are the most consequential negotiation points in the partnership structure.

The governance question. Minority equity holders in a PE-backed platform typically need explicit minority protection provisions to ensure their interests are protected during the hold period. Key governance terms to negotiate: information rights (regular financial reporting), consent rights on material practice-level decisions (capital expenditure thresholds, key personnel changes, related-party transactions), anti-dilution provisions if AmeriVet does follow-on equity raises, and clarity on how the partnership interacts with platform-level decisions.

The integration risk on retained equity. In partnership structures where the retained equity is tied to practice-level EBITDA performance, any integration decision AmeriVet makes that affects practice-level economics — shifting central services costs to the practice, renegotiating vendor contracts on platform-wide terms, changing the practice’s pricing or scheduling — can materially affect the seller’s eventual buyout value. Protective provisions in the partnership agreement that limit AmeriVet’s ability to make decisions that disadvantage the partnership-stake practice are among the most important contractual terms to negotiate.

For a broader walk-through of partnership vs. 100 percent acquisition structures across the veterinary M&A market, see our PE pricing guide.

How AmeriVet’s acquisition team operates

AmeriVet’s corporate-development team is structured around the partnership model in a way most of the PE-backed competitor teams are not. Per AmeriVet company materials, the team’s standard opening pitch leads with the partnership structure, the doctor-co-ownership framing, the operational platform that backs the partnership, and the put/call buyout mechanics that define the eventual exit.

The team is among the most active mid-market originators in the US veterinary buyer pool entering 2026 per the Capstone Partners and Octus 2025-2026 sector coverage.

Sourcing channels are the standard mix: direct outreach to identified practice owners, participation in structured competitive sale processes run by qualified sell-side advisors, and inbound inquiries from owners reaching out independently. The practical difference from most of the PE-backed pool is that AmeriVet’s direct outreach often arrives with a pre-built partnership term sheet rather than just a high-level indication of interest — the team uses the term sheet itself as the engagement tool, and that means the negotiation starts at a different place than a generic “indication of interest” conversation.

The competitive-process discipline matters more for AmeriVet deals because the structural terms (buyout formula, governance carve-outs, EBITDA protections) carry more long-term economic weight than the headline cash percentage, and those terms only move under competitive pressure.

How AmeriVet integrates the practices it acquires

AmeriVet’s integration approach is more operational than identity-changing per AmeriVet company materials. The platform emphasizes shared back-office services and operational support while preserving the local practice brand and customer-facing identity.

Local brand preservation. Per AmeriVet company materials, AmeriVet’s general approach is to preserve the practice name, signage, marketing materials, and local identity post-acquisition. The integration is focused on back-office and operational dimensions rather than on consolidating customer-facing brand.

The specific brand handling for any acquired practice is determined under the definitive purchase agreement on a case-by-case basis.

Shared back office. Per AmeriVet company materials, the platform provides centralized HR, accounting, payroll, vendor management, supply purchasing, and IT support. The integration timing and approach are determined case by case under AmeriVet’s regional operating structure.

Centralized marketing. Local marketing initiatives often consolidate into AmeriVet’s regional or national marketing programs, while the practice-level brand and customer-facing identity remain intact. The practice’s website typically remains under its original brand but may migrate to AmeriVet’s content management platform.

Continuing education and clinical programs. AmeriVet invests in continuing education and clinical programming for the doctors in its network per AmeriVet company materials. This is part of the platform’s broader value proposition for practitioners who join the network.

Doctor relationships. Per industry M&A commentary on PE-backed veterinary acquirers, selling owners commonly stay on as medical directors for 3 to 5 years post-close, providing continuity to staff and clients during the integration period. In partnership structures where the seller retains equity, the post-sale role is typically tied to the partnership terms and the eventual buyout timeline.

AmeriVet’s recent activity in 2025-2026

The 2025-2026 window has been a high-tempo period for AmeriVet’s acquisition pipeline. Capstone Partners‘ April 2026 Pet Sector M&A Update documents the broader sector acceleration entering Q1 2026, with the mid-market PE-backed segment that AmeriVet occupies leading the rebound.

Octus’s 2025 coverage of the veterinary roll-up category placed AmeriVet inside the top tier of US partnership-model bidders by transaction frequency. AmeriVet does not publicly itemize specific acquisition counts in real time, so any specific year-by-year count would need to be assembled from trade-press coverage and company announcements rather than from an authoritative AmeriVet source.

The practical implication for any owner receiving AmeriVet outreach in 2026: the team is running a sustained acquisition program with deep capital backing from AEA Investors and Oaktree Capital, and your specific deal sits inside a portfolio they’re actively building. The terms they offer on your practice reflect their pipeline-level economics, not a one-off opportunistic bid.

That’s actually useful information for the negotiation, because it means the formula and governance terms are more standardized — and therefore more negotiable through a properly structured competitive process — than a one-off strategic-buyer interaction would be.

Have an offer from AmeriVet? Get a Free AmeriVet Offer Review — send us the offer and we’ll decompose the terms (including the partnership equity terms, if applicable), identify what’s typically negotiable, and project what your practice would likely clear in a structured competitive process with the broader qualified buyer pool. No upfront cost, no obligation.

How AmeriVet compares to the other major buyers

If you’re considering AmeriVet, you’re probably comparing them implicitly to the other major buyers who’d compete for your practice. Here’s how AmeriVet stacks up across the dimensions that matter.

Versus NVA (JAB Holdings). NVA is owned by JAB Holdings, the Luxembourg-based privately-held investment vehicle of the Reimann family. NVA is structurally a long-hold strategic, distinguishing it from AmeriVet’s PE-backed fund-cycle ownership.

Both NVA and AmeriVet generally preserve local practice branding per company materials. Where they differ is the deal structure emphasis — AmeriVet has publicly emphasized partnership models as a distinguishing feature; NVA’s specific deal structures vary case by case.

Both participate in competitive sale processes for qualifying practices. Our NVA buyer profile covers the NVA-specific dimensions in depth.

Versus Mars Veterinary Health (VCA, BluePearl, Banfield). Mars is the strategic family-owned exception in the buyer pool per Mars company disclosures. Both Mars and AmeriVet participate in competitive processes for qualifying practices, with the specific deal terms determined case by case.

The structural difference matters most for sellers evaluating retained equity — Mars’s family-ownership horizon and AmeriVet’s PE-fund cycle operate on different timelines. AmeriVet has publicly emphasized partnership structures, while Mars’s specific posture on partnership structures is determined case by case.

Our Mars Veterinary Health buyer profile covers the Mars-specific dimensions in depth.

Versus VetCor (Harvest Partners). VetCor is PE-backed and one of the longer-established US veterinary consolidators per VetCor company materials. Both VetCor and AmeriVet operate with local-brand-preservation approaches per their respective company materials.

Both may compete for qualifying practices in a structured sale process; the specific deal terms and structure proposed by either buyer are determined case by case.

Versus Mission Pet Health. Mission Pet Health, the post-merger entity formed from SVP and MVP per the July 2025 Mission Pet Health press release, is an active 2026 acquirer with a meaningful Southeast and Sun Belt footprint. SVP (which became part of Mission Pet Health) has explicitly marketed partnership and co-ownership models in its company materials, similar to AmeriVet’s partnership-model emphasis.

Both Mission Pet Health and AmeriVet may compete for qualifying practices in a structured sale process; specific deal terms and partnership mechanics are best evaluated in context per practice.

Versus PetVet Care Centers (Ares Management). PetVet is PE-backed and operates a meaningful US footprint per PetVet company materials. Both PetVet and AmeriVet may compete for qualifying practices in a structured sale process; the specific deal terms are determined case by case.

Versus Thrive Pet Healthcare (formerly Pathway Vet Alliance, TSG Consumer Partners). Thrive is PE-backed and operates one of the larger US footprints per Thrive company materials. Both Thrive and AmeriVet may compete for qualifying practices in a structured sale process; the specific deal terms are determined case by case.

Versus the smaller PE-backed groups (Alliance Animal Health, Heartland, VPP, others). Each has its own integration philosophy and target profile. Smaller groups sometimes pay more aggressively for practices that fill specific geographic or specialty gaps in their portfolio.

The right way to evaluate which buyer pays most is to put all of them in a competitive process and let them surface their best offers in parallel.

What to negotiate before signing with AmeriVet

Seven priorities when negotiating with AmeriVet’s acquisition team, with the partnership terms as the highest-leverage category if AmeriVet proposes a partnership structure.

Partnership equity terms (highest priority if applicable). If AmeriVet’s offer includes a partnership or joint venture structure, the most consequential terms are: (1) the put/call buyout formula — what multiple is applied, what EBITDA base is used, what protective provisions guard the EBITDA calculation against post-acquisition changes; (2) the liquidity timeline — when can the seller exercise the put, when can AmeriVet exercise the call, are there interim liquidity events; (3) the governance rights — information rights, consent rights on material practice-level decisions, anti-dilution protections; (4) the integration protections — limits on AmeriVet’s ability to make decisions that disadvantage the partnership-stake practice (shifting central services costs to the practice, renegotiating practice-level contracts on terms that disadvantage the practice, etc.).

Cash at close percentage on the majority stake. Offers in this market generally lean toward the majority of total deal value as cash at close on the percentage AmeriVet is acquiring, but the specific percentage AmeriVet initially proposes varies deal by deal. Push for higher cash percentages on the acquired stake.

Every dollar shifted from contingent to cash is guaranteed money instead of conditional.

Earnout structure (if applicable). If the offer includes an earnout component on top of the partnership structure, earnouts commonly run on multi-year EBITDA targets. Push for shorter duration.

Push for revenue-based metrics where possible. Insist on protective provisions: no major operational changes without seller consent, working capital floor, prohibition on shifting expenses from other AmeriVet practices to the seller’s practice.

Brand handling. AmeriVet’s general approach is local brand preservation per company materials, but the specific brand handling deserves explicit confirmation in writing as part of the definitive purchase agreement. Negotiate explicit brand preservation language if local identity matters to your post-sale outcomes.

Non-compete scope. Non-competes commonly run several years and cover a defined geographic radius for all veterinary work. That can effectively end your career if you might want to continue practicing somewhere later.

Negotiate: shorter duration (1 to 2 years), tighter radius (5 to 10 miles), or carve out specific specialty or modality if you might continue clinical work post-employment.

Post-sale role and clinical autonomy. Medical director arrangements are standard. The protective terms that matter: clinical autonomy (you make medicine decisions, not the regional team), staffing autonomy (you keep the team you’ve trained), and a clear definition of which business decisions stay with you versus migrating to AmeriVet’s regional operating structure.

The integration roadmap should be in writing.

The exit alignment. AmeriVet, like every PE-backed platform, will eventually go through a platform-level exit event (the next sponsor sale, the recapitalization, or eventually an IPO). The timing of that event and how it interacts with the seller’s partnership equity deserves explicit contractual mechanics.

If the seller’s put right is exercisable before the platform exit, the formula price applies; if the put is structured to participate in the platform exit, the seller’s outcome is tied to platform-level valuation. Either approach can work, but the alignment needs to be explicit and consistent with the seller’s actual liquidity preferences.

The partnership-vs-100-percent choice

If AmeriVet offers both a partnership structure and a 100 percent acquisition alternative, the choice deserves explicit analysis.

A 100 percent cash acquisition gives the seller certainty on the entire deal value at close (minus any earnout component). The seller walks away from the practice’s future financial performance, both upside and downside.

The post-sale role and the continuing medical director arrangement are standalone employment terms, not tied to retained equity.

A partnership structure keeps the seller economically tied to the practice’s future financial performance through the retained 20 to 40 percent equity. The seller participates in upside if the practice grows, but also bears downside risk if integration decisions affect practice-level EBITDA.

The total deal value (cash at close plus eventual partnership buyout) can be materially higher than a 100 percent cash deal if the practice performs well and the buyout formula is favorably negotiated. But the partnership structure introduces additional complexity, additional contractual terms to negotiate, and additional time-to-full-liquidity.

The right choice depends on the seller’s specific circumstances: their certainty preference, their belief in the practice’s continued growth under AmeriVet ownership, their willingness to retain governance involvement, and their tolerance for the time and complexity of the partnership structure. There is no universally right answer, which is why the competitive process produces value — different buyers structure offers differently, and the seller can compare them side by side to find the structure that best matches their priorities.

Should I take an AmeriVet offer or run a competitive process?

For a partnership-structure deal, the competitive process matters more than it does for a straight 100-percent acquisition — not less. The reason is structural: a 100-percent acquisition has one big number to negotiate (the headline multiple, plus a few contingent components), while a partnership has six or eight terms that each carry significant long-term economic weight.

The put formula multiple. The EBITDA base definition.

The protective EBITDA-allocation clauses. The governance carve-outs.

The interim liquidity rights. The platform-exit alignment.

Each of these moves only under competitive pressure, and a direct one-on-one conversation with AmeriVet’s team produces movement on at most one or two of them.

A properly run competitive process puts the entire partnership term sheet on the table for negotiation simultaneously. Other partnership-model bidders — Mission Pet Health (with the legacy SVP partnership playbook), Rarebreed Veterinary Partners, regional specialty groups offering co-ownership variants, and where the practice profile fits, even the larger PE-backed platforms that occasionally offer partnership structures — each return their own term sheet, and the seller’s lawyers can read every clause against every other clause in parallel.

That comparison is where the real value emerges. AmeriVet then either matches the best terms it sees across the field or loses on a dimension it doesn’t have to lose on.

Either outcome is better for the seller than the one-on-one conversation would have produced.

What our Elite Selling System actually does

For an AmeriVet partnership deal, our process runs differently than it does for a straight 100-percent acquisition — because the negotiation is structural, not just numerical.

Step one: the structural diligence. We don’t start by valuing the practice. We start by deconstructing the AmeriVet term sheet against the partnership term sheets we’ve seen from the rest of the partnership-model buyer pool over the past 18 months.

Where does the AmeriVet put formula sit against the SVP/Mission Pet Health formula? Against Rarebreed’s?

What EBITDA-protection clauses are in their sheet, and which standard ones are missing? Where are the governance carve-outs softer than the comparable PE-backed minimum standards?

This audit identifies the negotiation surface area before the competitive process even starts.

Step two: the bidder curation. From the 42-plus named veterinary consolidators TE actively tracks, we invite only the ones whose profile genuinely competes with AmeriVet on this specific practice — geographic density, specialty mix, deal size band, and crucially, partnership-structure capability. Inviting a buyer that only does 100-percent acquisitions wastes a slot in the bidder window.

Inviting only partnership-model buyers handicaps the comparison the seller actually needs. The right mix is typically three or four partnership-model bidders alongside two or three 100-percent buyers, so the seller can see both structures clearly across the same practice.

Step three: the structured term-sheet comparison. The bidding window runs short and tight. Every bidder returns their full term sheet — not just the headline.

We arrange the sheets in a structural side-by-side matrix: cash-at-close percentage on the majority stake, retained-equity percentage and structure, put/call formula multiple, EBITDA base definition, protective clauses, governance carve-outs, liquidity timeline, non-compete scope, integration roadmap. The seller’s economic position under each scenario is modeled honestly, with present-value discounting and downside-case stress tests.

Then the seller chooses on the dimensions that matter to her — sometimes the highest nominal headline, sometimes the cleanest formula, sometimes the strongest governance protections.

The pattern holds across our partnership-deal exits: practices in the qualifying revenue band that run our process consistently clear materially better total economic outcomes — usually multiple seven figures, sometimes more — than the same practice would have cleared by signing AmeriVet’s direct term sheet without exploring the field.

Closing thought

The honest read on AmeriVet: among the US partnership-model veterinary buyers, AmeriVet has built one of the most refined and most replicable deal templates in the market. The dual-sponsor capital base (AEA Investors plus Oaktree Capital) supports a sustained acquisition cadence, the partnership term sheet they bring to direct conversations is more sophisticated than most of the competitor templates, and the brand-preservation posture is genuine.

What separates a good AmeriVet outcome from a mediocre one isn’t the cash multiple, and it isn’t even the retained-equity percentage. It’s the put formula, the EBITDA protections, the governance carve-outs, the liquidity timing.

Those terms determine whether the retained 20 to 40 percent equity grows or quietly erodes across the hold period. Those terms are also exactly the dimensions that respond most to competitive process discipline — which is why the partnership-deal seller who signs the direct term sheet typically leaves more on the table than the 100-percent-deal seller who does the same.

If an AmeriVet partnership term sheet is on your desk right now — or if the conversation is at the early-engagement stage and you’re being walked through how a partnership would look — the highest-leverage move is to understand what the partnership-structure field as a whole would offer for your specific practice before signing anything that pre-commits the structural terms. Get a Free Practice Value Estimate and we’ll lay out the same structural comparison we’d lay out for a client across a dinner table.

Sources

Industry M&A research and valuation data

1. Capstone Partners. Pet Sector M&A Update — April 2026. Capstone Partners industry research.
2. Octus. Veterinary Services Roll-Up Coverage, 2025-2026. Octus credit research and industry commentary.
3. Dechert LLP. Healthcare M&A: 2025-2026 Trends and Outlook. Dechert healthcare practice publications.
4. Holland & Knight. Healthcare Private Equity 2025-2026 Commentary. Holland & Knight healthcare practice publications.
5. MB Law Firm. 2025 Healthcare M&A Trends — Joint Venture and Partnership Structures. MB Law Firm healthcare publications.

AmeriVet and ownership materials

6. AmeriVet Veterinary Partners. About AmeriVet, partnership model, and US footprint. AmeriVet company materials, 2024-2026.
7. AEA Investors. Portfolio and healthcare services practice. AEA company materials.
8. Oaktree Capital. Portfolio and private equity practice. Oaktree company materials.

Veterinary practice operations, benchmarks, and profession data

9. iVET360. State of the Veterinary Industry — 2026 Industry Report. iVET360 industry research.
10. American Veterinary Medical Association (AVMA). 2026 AVMA Veterinary Economic Report. AVMA economic research.